Results 221 to 230 of about 872,427 (309)

SERUM AND CEREBRAL SPINAL FLUID COMPLEMENT AND SERUM AUTOANTIBODIES IN SYSTEMIC LUPUS ERYTHEMATOSUS

open access: bronze, 1971
Lawrence D. Petz   +3 more
openalex   +1 more source

Systemic Lupus Erythematosus [PDF]

open access: yesProceedings of the Royal Society of Medicine, 1971
openaire   +3 more sources

How we manage immune‐mediated thrombotic thrombocytopenic purpura after rituximab failure or intolerance

open access: yesBritish Journal of Haematology, EarlyView.
The use of rituximab as a pre‐emptive treatment in immune‐mediated thrombotic thrombocytopenic purpura (iTTP) is the current standard of care. However, for patients refractory to rituximab or for those with contraindication, further treatment guidelines are scarce.
Julia Weisinger   +4 more
wiley   +1 more source

Neurological Manifestations of Systemic Lupus Erythematosus: A Comprehensive Review. [PDF]

open access: yesCureus
Jayasinghe M   +11 more
europepmc   +1 more source

Oral mucosal ulceration in systemic lupus erythematosus

open access: bronze, 1978
Jeffrey D. Urman   +3 more
openalex   +1 more source

Systemic Lupus Erythematosus

open access: yesJournal of Investigative Dermatology, 1977
openaire   +2 more sources

Non‐canonical nitric oxide signalling and DNA methylation: Inflammation induced epigenetic alterations and potential drug targets

open access: yesBritish Journal of Pharmacology, EarlyView.
Abstract DNA methylation controls DNA accessibility to transcription factors and other regulatory proteins, thereby affecting gene expression and hence cellular identity and function. As epigenetic modifications control the transcriptome, epigenetic dysfunction is strongly associated with pathological conditions and ageing.
Christopher H. Switzer
wiley   +1 more source

Home - About - Disclaimer - Privacy